Zentalis Pharmaceuticals, Inc. (ZNTL)

NASDAQ: ZNTL · Real-Time Price · USD

3.705

+0.145 (4.07%)

At close: Aug 17, 2026, 4:00 PM EDT

3.770

+0.065 (1.75%)

After-hours: Aug 17, 2026, 7:55 PM EDT

Zentalis Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	-	67.43	-	-	-
Revenue Growth	-	-	-	-	-	-
Gross Profit	-	-	67.43	-	-	-
Selling, General & Admin	32.92	33.58	87.12	59.4	54.55	40.94
Research & Development	117.47	107.3	167.77	189.59	172.73	166.8
Operating Expenses	150.39	140.88	254.88	248.99	227.29	207.74
Operating Income	-150.39	-140.88	-187.46	-248.99	-227.29	-207.74
Interest & Investment Income	8.67	12.19	12.27	9.46	2.26	1.31
Earnings From Equity Investments	-	-	-	-16.01	-16.28	-1.83
EBT Excluding Unusual Items	-141.72	-128.69	-175.18	-255.54	-241.31	-208.26
Merger & Restructuring Charges	-	-7.8	-	-	-	-
Impairment of Goodwill	-	-	-3.74	-	-	-
Gain (Loss) on Sale of Investments	6.39	4	13.23	13.16	3.73	-0.91
Gain (Loss) on Sale of Assets	-0.53	-	-	-	-	51.58
Asset Writedown	-2.98	-4.14	-	-4.95	-	-8.8
Pretax Income	-138.85	-136.62	-165.69	-292.91	-237.58	-166.39
Income Tax Expense	0.7	0.44	0.18	-0.6	-0.47	-0.3
Earnings From Continuing Operations	-139.55	-137.06	-165.87	-292.31	-237.11	-166.09
Minority Interest in Earnings	-	-	0.03	0.11	0.31	7.37
Net Income	-139.55	-137.06	-165.84	-292.19	-236.81	-158.73
Net Income to Common	-139.55	-137.06	-165.84	-292.19	-236.81	-158.73
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	71	72	71	65	53	43
Shares Outstanding (Diluted)	71	72	71	65	53	43
Shares Change	-0.23%	1.11%	8.67%	23.75%	23.82%	51.84%
EPS (Basic)	-1.96	-1.91	-2.33	-4.47	-4.48	-3.72
EPS (Diluted)	-1.96	-1.91	-2.33	-4.47	-4.48	-3.72
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-128.13	-125.25	-171.08	-208.41	-166.3	-160.2
Free Cash Flow Per Share	-1.80	-1.74	-2.41	-3.19	-3.15	-3.75
Gross Margin	-	-	100.00%	-	-	-
Operating Margin	-	-	-278.02%	-	-	-
Profit Margin	-	-	-245.96%	-	-	-
Free Cash Flow Margin	-	-	-253.74%	-	-	-
EBITDA	-149.77	-140.14	-186.17	-247.6	-225.86	-207.2
EBITDA Margin	-	-	-276.11%	-	-	-
D&A For EBITDA	0.62	0.74	1.29	1.39	1.43	0.54
EBIT	-150.39	-140.88	-187.46	-248.99	-227.29	-207.74
EBIT Margin	-	-	-278.02%	-	-	-

SEC Filings: 10-K · 10-Q